Discussing big pharma at this point in time is extremely far...

Discussing big pharma at this point in time is extremely far fetched and caution well advised.

One - because there is no IP granted as yet.

Two - because there has not been one phase II trial yet and earlist is slated for 2020 and 2021 for the fastest track to market according to the CEO of noxopharm

Three - as this graph below shows phase one buyouts are the least unlikely.

Four - idronoxil is already well known and tagging on to successful drugs without double blinded studies to prove that any improvement is caused by idronoxil is hardly going to attack big pharm this early in the piece.

Five - according to the last 2ndQ report, a CR will be required by the end of this 3rd Q.

Six - the phase 1 PK study has been withdrawn and slated for a further date in the future again muddying the waters to data that would definitely be needed for any due diligence by big pharma to buy out.

7 - the desperation of some poster to run down others stocks that they don't own shows a kind of panic setting in, that confirms all of the above IMO.